DDInter1559 DDInter1658
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Rabeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Rabeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Rabeprazole {u} (Compound) binds {v} (Gene) CYP3A4
Rabeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Rabeprazole {u} (Compound) causes {v} (Side Effect) Fungal skin infection
Rabeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Rabeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Riociguat
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indinavir
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Neratinib
Rabeprazole (Compound) resembles Lansoprazole (Compound)
Rabeprazole (Compound) resembles Esomeprazole (Compound)
Rabeprazole (Compound) binds CYP3A4 (Gene)
Rabeprazole (Compound) downregulates THAP11 (Gene)
Rabeprazole (Compound) causes Fungal skin infection (Side Effect)
Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Indinavir
Rabeprazole may lead to a major life threatening interaction when taken with Neratinib